A U.S. federal judge in Missouri on Friday approved a $7.25 billion (€6.60 billion) settlement between German chemical giant Bayer and plaintiffs alleging that its Roundup weedkiller causes non-Hodgkin lymphoma, a type of blood cancer.
Judge Timothy Boyer ruled that the agreement is 'fair, reasonable, and adequate,' marking a key step toward resolving years of litigation tied to the product. The case originated when Bayer acquired Monsanto in 2018, inheriting legal claims related to Roundup's safety and labeling practices.
Scope of Compensation
The settlement covers tens of thousands of individuals who claim they developed non-Hodgkin lymphoma after using Roundup over time. It also includes potential future diagnoses resulting from prior exposure.
Bayer will distribute up to $7.25 billion into a dedicated fund over the next 21 years. Individual compensation is expected to range between $10,000 and $165,000, based on factors such as age at diagnosis, illness severity, and duration of exposure.
Sources indicate that some lawyers representing affected patients have criticized these figures as inadequate. However, Judge Boyer rejected those objections, stating that further delays could leave seriously ill individuals waiting for justice for more than a decade.
Legal Landscape Shifts
The settlement comes after a significant legal precedent set by the U.S. Supreme Court in June 2024. The court ruled that Bayer cannot be held liable under state laws for failing to include cancer warnings on Roundup packaging — asserting that federal regulations do not mandate such labels and that states lack authority to impose additional requirements.
This decision substantially weakened the ability of individual plaintiffs to pursue lawsuits over labeling issues related to Roundup. In October, a Missouri jury also sided with Bayer in another separate case involving similar claims.
Bayer reports approximately 200 litigation cases remain active in federal courts outside this settlement agreement.
Financial Impact and Historical Context
Monsanto introduced Roundup in 1974; its primary ingredient, glyphosate, became one of the world’s most widely used herbicides. It is commonly applied by farmers on genetically modified crops and has been extensively used in residential lawns and gardens.
Since acquiring Monsanto in 2018, around 200,000 claims have been filed against Bayer alleging that exposure to Roundup caused cancer. In a prior deal from 2020, Bayer agreed to pay $10.9 billion for past cases but failed to secure approval for coverage extending into future diagnoses.
Some lawsuits resulted in large payouts — including a $2.1 billion award granted to plaintiffs in Georgia. As of now, the company has set aside $16 billion specifically for Roundup-related legal expenses. Since its acquisition of Monsanto, Bayer’s stock value has declined by about 46%.
Safety and Scientific Debate
The scientific debate over glyphosate's carcinogenicity remains unresolved. In 2015, the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified glyphosate as 'probably carcinogenic' to humans. However, the U.S. Environmental Protection Agency maintains that glyphosate does not pose a cancer risk when used according to label instructions.
Bayer has consistently denied claims linking Roundup to cancer, citing regulatory approvals and peer-reviewed studies supporting its safety. This stance was challenged last year when a major study previously cited in support of Roundup’s safety was withdrawn by its publisher due to serious methodological flaws — including missing data and undisclosed involvement of Monsanto employees during research development.
The withdrawal raised concerns about potential conflicts of interest between chemical companies and scientific institutions conducting independent evaluations.
As of this report, no official confirmation exists regarding whether the settlement will cover all cases or address long-term health impacts beyond non-Hodgkin lymphoma. The full scope of medical outcomes remains under ongoing investigation.